Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain

NCT00549042 is registered in ClinicalTrials.gov with Mallinckrodt as lead sponsor.

NCT NCT00549042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00549042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain
Lead sponsor
Mallinckrodt
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
January 31, 2009
Enrollment
459 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic low back pain